 Home > Pharmaceutical Intermediates > Dermatological Agents > Crizotinib for Sale > Crizotinib API - A Potent ALK and ROS1 Inhibitor for NSCLC Treatment.

Crizotinib API - A Potent ALK and ROS1 Inhibitor for NSCLC Treatment. buy - large image1

Crizotinib API - A Potent ALK and ROS1 Inhibitor for NSCLC Treatment. buy - image1

Crizotinib API - A Potent ALK and ROS1 Inhibitor for NSCLC Treatment. buy - image2

Crizotinib API - A Potent ALK and ROS1 Inhibitor for NSCLC Treatment.

Name: Crizotinib API - A Potent ALK and ROS1 Inhibitor for NSCLC Treatment.
Brand: Tianrui
SKU: pr2511121364
Price: 11 USD
Availability: InStock

2 Inquiries

Unit Price: Get Latest Price 

CAS No.:

877399-52-5

Grade:

Pharmaceutical Grade

Content:

98.5%

Port:

Qingdao

Brand:

Tianrui

Packaging:

Sealed fiber drum

Price valid (until):

2025-11-12

Contact Supplier

 Chat Now

Hefei Tianrui Pharmaceutical Chemical Co., Ltd.

Company Type:

Manufactory

Location:

China

Qualification:

Main Products:

APIs

 Visit Store

Product Description
Seller Information
Inquiry History

Description

About Product

Crizotinib (CAS: 877399-52-5) is a high-purity, chiral active pharmaceutical ingredient (API) that functions as a potent tyrosine kinase inhibitor targeting ALK, ROS1, and MET receptors. Specifically developed for the treatment of ALK-positive and ROS1-rearranged non-small cell lung cancer (NSCLC), it represents a breakthrough in targeted cancer therapy. Manufactured by Hefei TianRui Pharmaceutical under strict cGMP conditions, our Crizotinib API guarantees high chiral purity, controlled impurities, and reliable quality for oncology drug formulations.

Items	Specifications
Product Name	Crizotinib
CAS Registry Number	877399-52-5
IUPAC Name	(R)-3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine
Molecular Weight	450.34 g/mol
Solubility	It is soluble in DMSO, soluble in methanol, and slightly soluble in water.
Melting Point	160-163°C
Primary Use	ALK-positive non-small cell lung cancer ROS1 rearrangement non-small cell lung cancer

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 1

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 2

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 3

Company Profile

Founded: 2014
Focus: High-tech enterprise specializing in the development and industrialization of small-molecule pharmaceutical synthesis technology
Facilities:
- Two workshops (TR1 & TR2) with total capacity ≈ 1000 tons/year
- Reactors: 3000L×15, 2000L×10, and numerous smaller reactors (1000L, 500L, 100L)
- Ultra-low temperature cryogenic reactor (explosion-proof workshop included)
- GMP workshop & clean room
QC Lab Equipment: GC×2, HPLC×3, UV, IR, KF titrator, etc.

About company

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 7

In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.

In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.

In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.

Basic Info

Product Name:

Crizotinib

Other Name:

2-Pyridinamine,3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-;3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine;[3-[[(R)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]oxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-yl]amine;PF 2341066;PF 02341066;Crizotinib;(R)-3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine;Xalkori;3-((R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine;912279-98-2

CAS No.:

877399-52-5

Molecular Formula:

C21H22Cl2FN5O

InChIKeys:

InChIKey=KTEIFNKAUNYNJU-GFCCVEGCSA-N

Molecular Weight:

450.343

Exact Mass:

450.34

EC Number:

1308068-626-2

UNII:

53AH36668S

NSC Number:

749005

NCI Thesaurus Code:

C74061

ATC Code:

L01XE16|L - Antineoplastic and immunomodulating agents

HScode:

29333990

Categories:

Dermatological Agents

Characteristics

PSA:

XLogP3:

3.7

Density:

1.5±0.1 g/cm3

Melting Point:

192 °C

Boiling Point:

599.177°C at 760 mmHg

Flash Point:

316.2±30.1 °C

Refractive Index:

1.673

See More Crizotinib Properties 

Hazard Identification

Classification of the substance or mixture

Skin sensitization, Category 1

Eye irritation, Category 2

Germ cell mutagenicity, Category 2

Hazardous to the aquatic environment, short-term (Acute) - Category Acute 1

GHS label elements, including precautionary statements

Precautionary statement(s)
Pictogram(s)
Signal word	Warning
Hazard statement(s)	H317 May cause an allergic skin reaction H319 Causes serious eye irritation H341 Suspected of causing genetic defects H400 Very toxic to aquatic life
Prevention	P261 Avoid breathing dust/fume/gas/mist/vapours/spray. P272 Contaminated work clothing should not be allowed out of the workplace. P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/... P264 Wash ... thoroughly after handling. P203 Obtain, read and follow all safety instructions before use. P273 Avoid release to the environment.
Response	P302+P352 IF ON SKIN: Wash with plenty of water/... P333+P317 If skin irritation or rash occurs: Get medical help. P321 Specific treatment (see ... on this label). P362+P364 Take off contaminated clothing and wash it before reuse. P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P318 IF exposed or concerned, get medical advice. P391 Collect spillage.
Storage	P405 Store locked up.
Disposal	P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

Other hazards which do not result in classification

no data available

Handling and Storage

Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

Conditions for safe storage, including any incompatibilities

Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

See More Crizotinib Safety Data Sheet 

Seller Information

Business Type:
Manufactory

Main Products:
APIs

Location:
No.23,lntersection of Fenglehe Avenue and Leiyang Road, Huagang Town,Feixi County, Hefei, Anhui, China.

Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Average lead Time:
15

Total Annual Revenue:
$50 million-$100 million

Total Employees:
11-50

Year of Establishment:
2014

About TianRui

Hefei TianRui Pharmaceutical Chemical Co., Ltd was founded in 2014 as a high-tech enterprise focused on the development and industrialization of pharmaceutical small molecule synthesis technology. Our workshop and R&D center are located in Hefei HuaGang Provincial Industrial Park, Anhui Province. We are committed to providing professional technical services and commercialization of small molecule specialty APIs, CGMP standard intermediates, and functional pharmaceutical excipients and MRNA vaccine vectors for domestic and overseas well-known pharmaceutical companies.

Main Events

In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.

In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.

In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.

Inquiry History

2 Inquiries

Country	Product	Purchase Quantity	Date Posted
Russia	Wholesale Crizotinib Raw Material Powder 99% White Powder CAS 877399-52-5 Crizotinib Powder	50 KG	Nov 19, 2023
Pakistan	Crizotinib	1 KG	Jun 20, 2025

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
Crizotinib(PF-02341066)	/99		Creative Enzymes	Inquiry
Crizotinib 877399-52-5	/99		ELITE CHEMICAL	Inquiry
Crizotinib, CAS:877399-52-5	Pharmaceutical Grade/99	$80-85/KG FOB	Guangzhou Yaoguang Technology Co., Ltd.	Inquiry
Crizotinib 877399-52-5	Pharmaceutical Grade/99		Shanghai RC Chemicals Co., Ltd	Inquiry
Crizotinib	/		Hangzhou Dawn Ray Pharmaceutical Co.,Ltd	Inquiry